CL2009000287A1 - A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the above bacterium, virus, fungus or parasite; method to develop the composition and use of sav. - Google Patents
A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the above bacterium, virus, fungus or parasite; method to develop the composition and use of sav.Info
- Publication number
- CL2009000287A1 CL2009000287A1 CL2009000287A CL2009000287A CL2009000287A1 CL 2009000287 A1 CL2009000287 A1 CL 2009000287A1 CL 2009000287 A CL2009000287 A CL 2009000287A CL 2009000287 A CL2009000287 A CL 2009000287A CL 2009000287 A1 CL2009000287 A1 CL 2009000287A1
- Authority
- CL
- Chile
- Prior art keywords
- inactivated
- sav
- parasite
- fungus
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Composición que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parásito y un material antigénico derivado de la bacteria, virus, hongo o parásito anterior; método para elaborar la composición y uso del sav.A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the previous bacterium, virus, fungus or parasite; method to elaborate the composition and use of sav.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20080711 | 2008-02-08 | ||
NO20080885 | 2008-02-20 | ||
NO20090290A NO333242B1 (en) | 2008-02-08 | 2009-01-20 | Composition, medical application and method comprising salmonid alphavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000287A1 true CL2009000287A1 (en) | 2010-08-27 |
Family
ID=40469649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000287A CL2009000287A1 (en) | 2008-02-08 | 2009-02-06 | A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the above bacterium, virus, fungus or parasite; method to develop the composition and use of sav. |
Country Status (4)
Country | Link |
---|---|
CA (2) | CA2653300C (en) |
CL (1) | CL2009000287A1 (en) |
GB (2) | GB2493662B (en) |
NO (2) | NO333242B1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2688587B2 (en) | 2011-03-25 | 2023-08-16 | Intervet International B.V. | Salmonid alphavirus vaccine |
DK178233B1 (en) | 2012-09-17 | 2015-09-14 | Novartis Tiergesundheit Ag | Fiskevaccine |
NO344938B1 (en) * | 2018-12-13 | 2020-07-20 | Patogen As | Pancreas Disease Virus Markers |
BE1028701B1 (en) * | 2020-10-13 | 2022-05-16 | Poulpharm Bvba | METHOD FOR AUTOVACCINE PRODUCTION AND OBTAINED AUTOVACCINE |
CN112877399B (en) * | 2021-01-20 | 2023-05-16 | 中国水产科学研究院黑龙江水产研究所 | Salmon and trout pathogenic bacteria drug sensitivity detection method, drug sensitivity detection kit and preparation method |
CA3230802A1 (en) * | 2021-08-31 | 2023-03-09 | Zoetis Services Llc | Attenuated alphavirus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0712926T3 (en) * | 1994-10-18 | 2004-02-09 | Akzo Nobel Nv | Virus causing pancreatic disease in fish |
US6719980B1 (en) * | 1998-05-08 | 2004-04-13 | Akzo Nobel Nv | Structural proteins of fish pancreatic disease virus and uses thereof |
AU2003229199A1 (en) * | 2002-05-31 | 2003-12-19 | Alpharma As | Liposome vaccine formulations for fin-fish |
DK179025B1 (en) * | 2005-09-16 | 2017-08-28 | Intervet Int Bv | fish vaccine |
CA2656032C (en) * | 2006-06-29 | 2017-06-13 | Pharmaq As | Process for culturing bacteria of the piscirickettsia genus |
-
2009
- 2009-01-20 NO NO20090290A patent/NO333242B1/en active Protection Beyond IP Right Term
- 2009-02-06 CL CL2009000287A patent/CL2009000287A1/en unknown
- 2009-02-06 GB GB1219654.9A patent/GB2493662B/en active Active
- 2009-02-06 CA CA2653300A patent/CA2653300C/en active Active
- 2009-02-06 CA CA3090088A patent/CA3090088C/en active Active
- 2009-02-06 GB GB0901913.4A patent/GB2457158B/en active Active
-
2015
- 2015-08-03 NO NO2015019C patent/NO2015019I1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2493662B (en) | 2013-04-17 |
GB2457158A (en) | 2009-08-12 |
CA3090088C (en) | 2023-01-31 |
NO20090290L (en) | 2009-08-10 |
GB2457158B (en) | 2013-04-03 |
GB2493662A (en) | 2013-02-13 |
NO333242B1 (en) | 2013-04-15 |
CA3090088A1 (en) | 2009-08-08 |
GB201219654D0 (en) | 2012-12-12 |
NO2015019I1 (en) | 2015-08-10 |
CA2653300A1 (en) | 2009-08-08 |
GB0901913D0 (en) | 2009-03-11 |
CA2653300C (en) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022018819A2 (en) | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | |
CL2009000287A1 (en) | A composition comprising an inactivated salmonid alphavirus (sav) and at least one component selected from a killed / inactivated bacterium, another inactivated virus, a fungus, a parasite and an antigenic material derived from the above bacterium, virus, fungus or parasite; method to develop the composition and use of sav. | |
CL2011001993A1 (en) | Immunogenic composition comprising at least one inactivated dengue virus antigen and an adjuvant without aluminum; Method of production; and its use to prevent, improve or treat a dengue virus productive disease in a subject. | |
CL2012000976A1 (en) | Antiperspirant composition comprising a base, an antiperspirant active and at least one antioxidant; and method of reducing or eliminating yellowing in clothing. | |
AR064009A1 (en) | IMMUNIZATION METHOD AGAINST THE 4 SEROTIPS OF DENGUE | |
ECSP10010548A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
CY1113666T1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF THE DEPARTMENT AND THE METHOD OF PREPARATION | |
UY33297A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A POLYPEPTIDE THAT UNDERSTANDS AT LEAST A CXXC REASON AND HETEROLOGICAL ANTIGENS AND USES OF THE SAME | |
AR083395A1 (en) | NMU PEPTIDIC DERIVATIVE (NEUROMEDINA U) WITH ELEVATED ANORECTIC EFFECT | |
AR056733A1 (en) | USE OF VACCINES FOR THE TREATMENT / PREVENTION OF THE TRANSMISSION OF PATHOGENS | |
CR8638A (en) | AGALACTIAE ESTREPTOCOCOS VACCINE | |
MX2020004543A (en) | Zika vaccines and immunogenic compositions, and methods of using the same. | |
CL2015001329A1 (en) | Composition for immersion treatment of plant roots. | |
AR108829A1 (en) | VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS | |
CO6361948A2 (en) | USE OF MYCOPLASMA BOVIS ANTIGEN | |
PH12016500946A1 (en) | Composition for preventing and curing mycoplasma infection | |
CO2021010786A2 (en) | Inactivated apxia, apxiia, and apxiiia toxins | |
CL2016000300A1 (en) | Therapeutic methods | |
CL2011001284A1 (en) | Procedure for the production of vaccines against bacterial pathogens that produce an ab toxin; vaccine comprising clostridium toxoid a and / or b; use of said vaccine against infections of pathogens that produce toxins ab. | |
CL2017001595A1 (en) | Vaccine compositions for dengue virus and methods of use thereof | |
BR112018014723A2 (en) | bacterial ghosts for cancer treatment | |
AR052639A1 (en) | VACCINE COMPOSITION AGAINST THE VIRUS OF HEPATITIS C. | |
NI201900006A (en) | COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE | |
MA42317B2 (en) | Combination vaccine composition for multiple administration | |
CL2021000107A1 (en) | Methods of treating hfpef using dapagliflozin and compositions comprising the same |